Literature DB >> 12447702

Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors.

Dong Yin1, Dong Xie, Wolf-Karsten Hofmann, Carl W Miller, Keith L Black, H Phillip Koeffler.   

Abstract

Methylation status of the p15(INK4B), p16(INK4A), p14(ARF) and retinoblastoma (RB) genes was studied using methylation specific polymerase chain reaction (MSP) in 85 human brain tumors of various subtypes and four normal brain samples. These genes play an important role in the control of the cell cycle. Twenty-four out of 85 cases (28%) had at least one of these genes methylated. The frequency of p14(ARF) methylation was 15 out of 85 (18%) cases, and the expression of p14(ARF) in methylated gliomas was significantly lower than in unmethylated gliomas. The incidence of methylation of p15(INK4B), p16(INK4A) and RB gene was 4%, 7%, and 4%, respectively. Samples with p14(ARF) methylation did not have p16(INK4A) methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14(ARF). Also, the p14(ARF) expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by down-regulating expression of p14(ARF). In summary, inactivation of the apoptosis pathway that included the p14(ARF) and p53 genes by hypermethylation and mutation, respectively, occurred frequently in human brain tumors. Down-regulation of p14(ARF) in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447702     DOI: 10.1038/sj.onc.1206031

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

2.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

3.  Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.

Authors:  Ganeshkumar Rajendran; Karthik Shanmuganandam; Ameya Bendre; Dattatraya Muzumdar; Dattatreya Mujumdar; Abhay Goel; Anjali Shiras
Journal:  J Neurooncol       Date:  2011-01-13       Impact factor: 4.130

4.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors:  Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  Aberrant CpG island methylation of multiple genes in ependymal tumors.

Authors:  M Eva Alonso; M Josefa Bello; Pilar Gonzalez-Gomez; Dolores Arjona; Jose M de Campos; Manuel Gutierrez; Juan A Rey
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

6.  Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation.

Authors:  Li-Ming Wu; Feng Zhang; Lin Zhou; Zhe Yang; Hai-Yang Xie; Shu-Sen Zheng
Journal:  BMC Cancer       Date:  2010-08-02       Impact factor: 4.430

Review 7.  Epigenetic changes in gliomas.

Authors:  Rebecca Burgess; Robert Jenkins; Zhiguo Zhang
Journal:  Cancer Biol Ther       Date:  2008-09-18       Impact factor: 4.742

8.  Retinoblastoma (RB1) pocket domain mutations and promoter hyper-methylation in head and neck cancer.

Authors:  Maimoona Sabir; Ruqia Mehmood Baig; Kashif Ali; Ishrat Mahjabeen; Muhammad Saeed; Mahmood Akhtar Kayani
Journal:  Cell Oncol (Dordr)       Date:  2014-06-03       Impact factor: 6.730

9.  Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients.

Authors:  Aleksandra Majchrzak-Celińska; Jarosław Paluszczak; Robert Kleszcz; Marta Magiera; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2013-05-10       Impact factor: 3.240

10.  Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.

Authors:  Nhan Lu-Chinh Phan; Ngu Van Trinh; Phuc Van Pham
Journal:  Onco Targets Ther       Date:  2015-12-23       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.